Published in Blood Weekly, October 1st, 2009
"We describe adverse events of this therapy in detail and we find that the tolerance of maintenance therapy may depend on the race," wrote S. Nagai and colleagues, University of Tokyo, Medical Department.
The researchers concluded: "Our results indicate that the race and dose intensity should be considered in addition to the number of consolidation courses...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.